Enzo Biochem (ENZ) Tops Q1 EPS by 2c

Enzo Biochem (NYSE: ENZ) reported Q1 EPS of ($0.03), $0.02 better than the analyst estimate of ($0.05). Revenue for the quarter came in at $26.3 million versus the consensus estimate of $25.9 million.

On October 31, 2016, cash and cash equivalents totaled $67.2 million, and working capital was $69.7 million. Consolidated cash flows used in operation was only $334,000 in the current year quarter. With the retirement in December 2016 of our outstanding bank loan, the Company, apart from lease obligations, currently has no outstanding debt.

For earnings history and earnings-related data on Enzo Biochem (ENZ) click here.

You May Also Be Interested In

• BofA expects Apple to top analyst expectations on July 30
• Wells Fargo cuts HubSpot to Equal Weight as AI transition clouds near-term outlook
• Morgan Stanley upgrades Global Payments to Overweight on Worldpay optimism